Participants 50 118 4
hyperglycemic patients with non-ST elevation acute coronary syndrome
Participants 282 430 6
in patients with diabetes receiving standard treatment for diabetes and randomized to ranolazine or placebo within the MERLIN-TIMI-36 (MERLIN) study
Participants 691 762 5
patients with diabetes and A1C of >or=8-10% at randomization (n = 171),
Participants 862 888 3
placebo-adjusted (n = 182)
Participants 968 1073 3
patients with FPG of 150-400 mg/dl at randomization, ranolazine (n = 131) compared with placebo (n = 147)
Participants 1709 1776 3
patients with cardiovascular disease and poorly controlled diabetes
